ScanBalt Business advertiser TBD-Biodiscovery to present at a press study tour 28 – 30 May to Copenhagen
CEO Andrus Tasa from TBD-Biodiscovery in Tartu will present the company and its activities during a press study tour to Copenhagen for selected journalists 28 – 30 May 2013.
The press study tour is part of the HealthPort project co-financed by the Baltic Sea Region Programme 2007 – 2013 and TBD-Biodiscovery is a winner of the HealthPort Innovation award 2012 organised by Culminatum Innovation Oy Ltd.
TBD-Biodiscovery is a centre for manufacturing and development of active pharmaceutical ingredients (both API and HPAPI) and intermediates. Their special expertise covers multistep synthesis of organic compounds and preparation of pheromones, anthracyclines and peptidomimetics.
TBD-Biodiscovery has a solid track of complicated R&D projects successfully accomplished and active pharmaceutical ingredients are produced under highest European GMP standards. For several years TBD-Biodiscovery has provided top class services for biotech, pharma and drug development companies all over the world, including world leaders in pharma industry.
ScanBalt Business responsible and coordinator of HealthPort, Peter Frank, General Secretary in ScanBalt says “We are happy to be able to offer support and services to distinguished companies like TBD-Biodiscovery. It is our hope that ScanBalt Business will compliment our constant efforts to promote ScanBalt BioRegion as a globally competitive health and bio economy”.
16 May 2023
Workshop"AI in clinical diagnostics: challenges and opportunities"| 7 June 2023 17:30-19:00 CET (Hybrid)